Drug Manufacturers’ 340B Restrictions Generate New Round Of Media Scrutiny & Criticism
Proxsys Rx
AUGUST 16, 2023
“Don’t believe drug companies: 340B is a program worth saving” On Tuesday, August 8, The Hill published a guest editorial (title above) by John Hassell — national director of advocacy at the AIDS Healthcare Foundation (AHF). First, start with presenting drug company-funded research as if it is non-biased. drug market.
52 
Let's personalize your content